Status:
UNKNOWN
Interaction Between Nalbuphine and Morphine in PCA
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Postoperative Pain
Eligibility:
FEMALE
18-65 years
Phase:
PHASE4
Brief Summary
1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist 2. This study was designed to investigate the interaction between nalbuphine and morphine
Detailed Description
1. Nalbuphine is opioid mu receptor antagonist and kappa receptor agonist 2. This study was designed to investigate the interaction between nalbuphine and morphine 3. The analgesic effect and opioid-r...
Eligibility Criteria
Inclusion
- Age 18-65 y/o
- Female patients of ASA physical status I to III
- Scheduled for elective abdominal hysterectomy, myomectomy, or excision of ovarian tumor
Exclusion
- Patients with a definite diagnosis of chronic pain syndrome, psychiatric disorders, or drug abuse (include opioids, NSAIDs, sedatives, antidepressants)
- Intraoperative fentanyl use \> 3 μg/kg
- Patients with definite diagnosis of esophageal reflux syndrome
- Use of sedatives, antiemetics, or antipruritics within 24 hours before operation
- Surgery \> 4 hours or laparoscopy surgery
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT00155233
Start Date
January 1 2005
Last Update
November 23 2005
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan, 100